Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of
diabetes mellitus.[6][7][8][9] It contains
insulin degludec and
insulin aspart.[6] It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh.[6]
The most frequently reported side effect is
hypoglycemia (low blood glucose levels).[6]
It was approved for medical use in the European Union in January 2013,[6] and in Australia in November 2017.[2]
Medical uses
Insulin degludec/insulin aspart is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of two years.[6]
Insulin degludec and insulin aspart are slightly different from human insulin.[6] The differences mean that insulin degludec is absorbed more slowly by the body.[6] This means it has a long duration of action.[6] Meanwhile, insulin aspart is absorbed faster by the body than human insulin, and therefore it starts to work as soon as it is injected and has a short duration of action.[6]